Inclusion Criteria:

          -  Male or female patients ≥18 years of age. For Japan only: written consent is necessary
             both from the patient and his/her legal representative if he/she is under the age of
             20 years.

          -  Histologically documented advanced or metastatic solid tumors or lymphomas Part 1:
             histologically confirmed renal cell carcinoma (RCC), pancreatic cancer, urothelial
             cancer, head and neck cancer, diffuse large B-cell lymphoma (DLBCL), microsatellite
             stable (MSS) colon cancer, triple negative breast cancer (TNBC), melanoma, metastatic
             castration resistant prostate cancer (mCRPC) Part 2: histologically confirmed
             diagnosis of advanced/metastatic NSCLC. For those with mixed histology, there must be
             a predominant histology Part 3: histologically confirmed diagnosis of selected
             advanced/metastatic malignancies. Part 3 will be opened to further assess TNBC
             patients with a PD-L1 SP-142 IC score of 0 (<1%). A second tumor group will be
             considered for Part 3 after completion of Part 1.

          -  Patient (except for those participating in Japanese safety run-in) must have a site of
             disease amenable to biopsy, and be a candidate for tumor biopsy according to the
             treating institution's guidelines. Patient must be willing to undergo a new tumor
             biopsy at screening, and again during therapy on this study.

          -  Safety run-in part in Japanese patients can enroll any tumor type included in part 1,
             2 and 3.

        The collection of recent sample is permitted under the following conditions (both must be
        met):

        Biopsy was collected ≤ 6 months before 1st dose of study treatment and available at the
        site.

        No immunotherapy was given to the patient since collection of biopsy.

        - Part 1 - 3 only: Patients (other than those with DLBCL) must previously have received at
        least 1 and no more than 3 prior lines of therapy for their disease (with the exception of
        IO-pretreated cutaneous melanoma, HNSCC and RCC), unless considered inappropriate for the
        patient (e.g. safety concern, label contraindication): Patients with NSCLC must have
        received a prior platinum-based combination. Patients with EGFR positive NSCLC with a T790M
        mutation must have progressed on osimertinib or discontinued due to toxicity.

        Patients with head and neck cancer must have received a prior platinum-containing regimen.

        Patients with bladder cancer must have received a prior platinum-containing regimen or be
        ineligible for cisplatin.

        Patients with renal cell carcinoma must have received a prior VEGF tyrosine kinase
        inhibitor (TKI).

        Patients with MSS colorectal cancer must have received (or be intolerant to) prior therapy
        with fluoropyrimidine-oxaliplatin- and irinotecan- based regimens.

        Patients with triple negative breast cancer:. Part 1: must have received a prior
        taxane-containing regimen Part 3: should have received no more than 2 prior lines of
        therapy including taxane-based chemotherapy and should have a known PD-L1 status as per
        local available testing as determined by VENTANA PD-L1 SP142 Assay with IC score of 0 (<1%)
        Patients with DLBCL should be limited to those with no available therapies of proven
        clinical benefit Patients should have had prior autologous hematopoietic stem cell
        transplantation (auto-HSCT) or determined to be ineligible for auto-HSCT.

        Patients with melanoma:

        BRAF V600E wild type patients: must have received anti-PD-1/PD-L1 single agent, or in
        combination with anti-CTLA-4 therapy BRAF V600E mutant patients: must have received prior
        anti-PD-1/PD-L1 single-agent, or in combination with anti-CTLA-4 therapy. In addition,
        subjects must have received prior BRAF V600E inhibitor therapy, either single-agent or in
        combination with a MEK inhibitor

        Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC):

          -  Of the 1-3 prior lines of therapy, patients must have received and failed at least one
             line of treatment after emergence of castration resistant disease

          -  Patients must not have received prior immunotherapy (previous immune checkpoint
             inhibitors; single agent and/or combination therapy with anti-CTLA-4, anti-PD-1,
             anti-PD-L1), except for NSCLC patients enrolled in part 3 and Japanese safety run-in
             part.

          -  Patients must have measurable disease, defined as at least one lesion that can be
             accurately measured in at least one dimension (longest diameter to be recorded for
             non-nodal lesions and short axis for nodal lesions) as >20 mm with conventional
             techniques or as >10 mm with spiral computer tomography (CT) scan, Magnetic Resonance
             Imaging (MRI), or calipers by clinical exam.

        Exclusion Criteria:

          -  Ongoing or prior treatment with A2aR inhibitors. Patients previously treated with A2aR
             inhibitors for non-oncologic indications (e.g. Parkinson's disease) may be considered
             for enrollment on a case by case basis.

          -  Current or prior use of immunosuppressive medication within 28 days before the first
             dose of PDR001, with the exception of intranasal/inhaled corticosteroids or systemic
             corticosteroids at physiological doses (not exceeding equivalent of 10 mg/day of
             prednisone)

          -  History of another primary malignancy except for:

        Malignancy treated with curative intent and with no known active disease ≥2 years before
        the first dose of study drug and of low potential risk for recurrence Adequately treated
        non-melanoma skin cancer or lentigo maligna without evidence of disease Adequately treated
        carcinoma in situ without evidence of disease

          -  Active or prior documented autoimmune disease within the past 2 years. Patients with
             vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within the
             past 2 years) are not excluded.

          -  More than 3 prior lines of therapy except for Japanese safety run-in part.

          -  History of interstitial lung disease or non-infectious pneumonitis

          -  Systemic anti-cancer therapy within 2 weeks of the first dose of study treatment. For
             cytotoxic agents that have major delayed toxicity, e.g. mitomycin C and nitrosoureas,
             6 weeks is indicated as washout period. For patients receiving anticancer
             immunotherapies, 4 weeks is indicated as the washout period. GnRH therapy to maintain
             effective testosterone suppression levels is allowed for mCRPC patients.

        Other protocol-defined exclusion criteria may apply.